Fig. 1 · Structure

Documents & Downloads

Saxagliptin (BMS-477118)

Cat. No. A11109 CAS 361442-04-8

DPP-4 Inhibitor

Saxagliptin (BMS-477118) is a new dipeptidyl peptidase-4 (DPP-4) inhibitor with IC50 of 50 nM.

In Stock

Publications for Saxagliptin

5 publications citing this product

  1. Ki-Young Kim, .et al. , Pharmaceutics, 2024, Jan 13;16(1):106 PMID: 38258116
  2. OHE El-Shoubashy, .et al. , JPC, 2020, 33, 59-70
  3. Sato T, .et al. , Sci Rep, 2019, Dec 2;9(1):18094 PMID: 31792328
  4. Chintan N. Koyani, .et al. , Front Physiol, 2018, 9: 1622 PMID: 30487758
  5. Koyani CN, .et al. , Biochem Pharmacol, 2016, Dec 1;145:64-80 PMID: 28859968

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Saxagliptin inhibits DPP4 competitively. In an isolated human-enzyme assay at 37°C, reported Ki values were 1.3 ± 0.3 nM for DPP4, 508 ± 174 nM for DPP8 and 98 ± 44 nM for DPP9 (mean ± SD). These results show relative selectivity and measurable DPP8/9 inhibition. The study tested saxagliptin monohydrate synthesized at Bristol-Myers Squibb. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
DPP-4 26 nM

Cellular Effect

Cell Line Activity Value Description Reference
Caco-2 IC50 50 nM Inhibition of DPP4 in human Caco2 cells using H-Ala-Pro-7-amido-4-trifluoromethylcoumarin as substrate after 1 hr by fluorescence assay [PMID: 23623674]
U-87MG ATCC IC50 1720 μM Inhibition of FAP in human U87MG cells using Suc-Gly-Pro-AMC as substrate by fluorescence based assay [PMID: 32527554]

Saxagliptin (BMS-477118) Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Saxagliptin (BMS-477118) from 3 published references. In vitro models include isolated cloned human DPP4, DPP8 and DPP9 at 37°C.

Saxagliptin (BMS-477118) In Vitro Studies

In HL-1 cardiomyocytes, saxagliptin reduced PKC activity in a time- and concentration-dependent manner, whereas sitagliptin did not. DPP9 knockdown reproduced the reduction and abolished the additional saxagliptin response; DPP8 knockdown did not. This supports a model-specific DPP9-dependent effect and does not establish direct PKC inhibition or a clinical heart-failure mechanism. The paper names Adooq as the supplier but does not specify the tested salt or hydration state. [2]

Human DPP4 inhibition and DPP8/9 selectivity

Biochemical assay · Isolated cloned human DPP4, DPP8 and DPP9 at 37°C [1]

Saxagliptin competitively inhibited DPP4 more potently than DPP8 or DPP9. Selectivity is relative: measurable DPP8/9 inhibition was retained in the enzyme panel.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Human DPP4 inhibitionKi 1.3 ± 0.3 nM (12 independent experiments; mean ± SD)[1]
Human DPP8 inhibitionKi 508 ± 174 nM (13 independent experiments; mean ± SD)[1]
Human DPP9 inhibitionKi 98 ± 44 nM (11 independent experiments; mean ± SD)[1]

Literature-Reported Treatment Conditions

Treatment concentration
Various inhibitor concentrations; Gly-Pro-pNA at 120 or 1000 μM
Exposure duration
40 min enzyme–inhibitor preincubation; product monitored over 40 min
Method
Absorbance at 405 nm; pH 7.4; 37°C
Vehicle
1% DMSO (final)
Reported limits
Exact inhibitor concentration series not specified in this Methods section.
Methods and source locations

Compound reported in the paper: Saxagliptin (BMS-477118); Compound label in the paper: Saxagliptin

Compound-level enzyme evidence; not a measured potency of catalog stock or a treatment concentration.

Table 2; Results: potency/selectivity for human enzymes at 37°C; Methods: Reagents and steady-state inhibition

Human DPP4 inhibition: Gly-Pro-pNA cleavage; IC50 converted to Ki using the competitive-inhibition equation and averaged across two substrate concentrations. — Table 2; Results: potency/selectivity for human enzymes at 37°C; Methods: Reagents and steady-state inhibition

Human DPP8 inhibition: Same steady-state assay framework as DPP4. — Table 2; Results: potency/selectivity for human enzymes at 37°C; Methods: Reagents and steady-state inhibition

Human DPP9 inhibition: Same steady-state assay framework as DPP4. — Table 2; Results: potency/selectivity for human enzymes at 37°C; Methods: Reagents and steady-state inhibition

DPP9-dependent reduction of PKC activity in HL-1 cells

Cell-based study · HL-1 murine cardiomyocyte cell line, including DPP8- or DPP9-silenced cells [2]

Saxagliptin reduced active PKC levels; sitagliptin did not. DPP9 knockdown reduced PKC activity and removed the additional saxagliptin response, whereas DPP8 knockdown did not. This supports a DPP9-dependent cellular pathway, without establishing direct inhibition of PKC.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Active PKC in HL-1 cellsTime/concentration response Reduction reported from 2.5 min at 2 μM and from 1 μM after 10 min; n = 6 experiments, mean ± SEM; p < 0.05 vs corresponding baseline.[2]
PKC response after DPP isoform silencingMechanistic control DPP9 silencing lowered PKC activity and abolished the additional saxagliptin effect; DPP8 silencing did not; n = 6 experiments.[2]

Literature-Reported Treatment Conditions

Treatment concentration
2 μM for time course and knockdown experiments; 0–2 μM in concentration series
Exposure duration
Time course 0–30 min; 10 min concentration and knockdown drug exposures
Method
Cell treatment; PKC activity in lysates
Vehicle
0.01% (v/v) DMSO, final concentration in shared HL-1 incubation protocol
Co-treatment
Separate comparator arms: sitagliptin; TC-E 5007; DPP8/DPP9 or scrambled siRNA. Not a saxagliptin–sitagliptin combination.
Reported limits
No numerical PKC concentrations extracted from curves; no clinical exposure equivalence established.
Methods and source locations

Compound reported in the paper: Saxagliptin (BMS-477118); Compound label in the paper: Saxagliptin

Cultured-cell pathway evidence; does not prove a clinical heart-failure mechanism.

Figure 5A–D image/caption; Figure 4A–B knockdown validation; Results: Saxagliptin Inhibits PKC Activity, Dependent on DPP9; Methods: Incubation Protocol, Gene Silencing and PKC Activity Assay

Active PKC in HL-1 cells: PKC kinase activity kit ADI-EKS-420A; Figure 5A–B; one-way ANOVA with Tukey post hoc test. — Figure 5A–D image/caption; Figure 4A–B knockdown validation; Results: Saxagliptin Inhibits PKC Activity, Dependent on DPP9; Methods: Incubation Protocol, Gene Silencing and PKC Activity Assay

PKC response after DPP isoform silencing: Figure 5D; scrambled-siRNA control, DPP8 versus DPP9 silencing and sitagliptin comparison. Figure 4A–B and related text supply knockdown validation; no exact knockdown percentage inferred from images. — Figure 5A–D image/caption; Figure 4A–B knockdown validation; Results: Saxagliptin Inhibits PKC Activity, Dependent on DPP9; Methods: Incubation Protocol, Gene Silencing and PKC Activity Assay

Saxagliptin (BMS-477118) In Vivo Studies

Following single oral doses in cynomolgus monkeys, saxagliptin inhibited ex vivo plasma DPP activity at 24 hours. The two assay formats gave statistically similar saxagliptin results, while sitagliptin results differed by assay. The biomarker therefore requires assay-specific interpretation; it is not a direct measurement of glucose lowering. [1]

In lean male C57BL/6N mice, a single oral saxagliptin dose produced dose-dependent plasma DPP4 inhibition measured 70 minutes later. The saxagliptin series in Figure 3 spans 0.01–1 mg/kg. Results were normalized to the vehicle group and were uncorrected for plasma dilution; they describe acute target engagement under this assay. [3]

Monkey plasma DPP inhibition depends on assay and inhibitor

Animal study · Male and female cynomolgus monkeys; six per dose group; weekly crossover dosing [1]

Saxagliptin produced persistent ex vivo plasma DPP inhibition at 24 h. Assay concordance for saxagliptin contrasted with substrate-dependent detection of sitagliptin inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Plasma DPP activity at 24 hDose response and assay comparison Saxagliptin: significant vs vehicle at 1, 3 and 10 mg/kg with Ala-Pro-AFC; no significant between-assay difference at any saxagliptin dose.[1]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Single dose per weekly crossover period
Treatment course
24 h postdose endpoint
Vehicle
Water, final pH 5.0
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Saxagliptin crossover dose series
0.1, 0.3, 1, 3 or 10 mg/kg
Vehicle alone; sitagliptin dose series; two assays on the same plasma samplesAt 24 h, 1, 3 and 10 mg/kg differed significantly from vehicle in the Ala-Pro-AFC assay; saxagliptin results did not differ significantly between the two assays at any tested dose.[1]
Saxagliptin crossover dose series
Model: Male and female cynomolgus monkeys; six per dose group; weekly crossover dosing
Reported limits: Exact crossover sequence and total number of unique animals are not specified in the read Methods.
Methods and source locations

Compound reported in the paper: Saxagliptin (BMS-477118); Compound label in the paper: Saxagliptin

Animal pharmacodynamic biomarker evidence; no glucose efficacy or clinical equivalence claim.

Figure 4 image/caption and Results: Measurement of plasma DPP activity in ex vivo assays; Methods: monkey crossover, both plasma assays and statistical analysis

Plasma DPP activity at 24 h: Ala-Pro-AFC fluorescence at room temperature versus Gly-Pro-pNA absorbance at 30°C on identical plasma samples; Dunnett comparison to vehicle, Tukey HSD pairwise comparisons. — Figure 4 image/caption and Results: Measurement of plasma DPP activity in ex vivo assays; Methods: monkey crossover, both plasma assays and statistical analysis

Saxagliptin crossover dose series · Figure 4 image/caption and Results: Measurement of plasma DPP activity in ex vivo assays; Methods: monkey crossover, both plasma assays and statistical analysis

Acute oral saxagliptin inhibits mouse plasma DPP4

Animal study · Male C57BL/6N mice, 7–12 weeks, 19–26 g; n = 20–28/group in the ex vivo cohort [3]

Saxagliptin dose-dependently inhibited plasma DPP4 activity after an oral dose in lean mice. This is a separate target-engagement cohort from the paper’s glucose-tolerance cohort.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Plasma DPP4 inhibition at 70 minDose response Dose-dependent inhibition; Figure 3 shows mean (SD). No exact inhibition percentages extracted.[3]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Single administration
Treatment course
70 min after inhibitor dose; 10 min after oral dextrose challenge
Vehicle
0.25% methylcellulose, 5 mL/kg
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Saxagliptin acute target-engagement series
0.01, 0.03, 0.1, 0.3 and 1 mg/kg (saxagliptin points in Figure 3)
Vehicle; vehicle plus water challenge control; other DPP4 inhibitors tested separatelyPlasma DPP4 inhibition increased with saxagliptin dose. Exact percentages were not transcribed from the graph.[3]
Saxagliptin acute target-engagement series
Model: Male C57BL/6N mice, 7–12 weeks, 19–26 g; n = 20–28/group in the ex vivo cohort
Reported limits: Per-dose n within the stated 20–28/group range is not provided; no predose sample was collected.
Methods and source locations

Compound reported in the paper: Saxagliptin (BMS-477118); Compound label in the paper: Saxagliptin

Lean-mouse target engagement; not chronic diabetes efficacy, clinical efficacy or a quantitative cross-paper potency comparison.

Figure 3 image/caption; Methods 2.1 Reagents/Animals and 2.3 Measurement of murine plasma DPP-4 activity ex vivo; Results 3.3

Plasma DPP4 inhibition at 70 min: Continuous fluorescence Gly-Pro-AMC assay; 50% plasma, 50 μmol/L substrate; activity normalized to arithmetic mean of vehicle group rather than within-animal predose activity. — Figure 3 image/caption; Methods 2.1 Reagents/Animals and 2.3 Measurement of murine plasma DPP-4 activity ex vivo; Results 3.3

Saxagliptin acute target-engagement series · Figure 3 image/caption; Methods 2.1 Reagents/Animals and 2.3 Measurement of murine plasma DPP-4 activity ex vivo; Results 3.3

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 361442-04-8
Applications DPP-4 Inhibitor
Formula C18H25N3O2
Molecular Weight 315.4
Synonyms BMS-477118; Onglyza
SMILES
C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)CC(C5)(C4)O)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 62 mg/mL (196.57 mM)
Water 62 mg/mL (196.57 mM)
Ethanol 24 mg/mL (76.09 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
Saline

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Saxagliptin (BMS-477118) Research References

  1. [1] Wang A, Dorso C, Kopcho L, et al. Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor BMC pharmacology (2012). PMID: 22475049 DOI: 10.1186/1471-2210-12-2 Source material
  2. [2] Koyani CN, Trummer C, Shrestha N, et al. Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes Frontiers in physiology (2018). PMID: 30487758 DOI: 10.3389/fphys.2018.01622 Source material
  3. [3] Berger JP, SinhaRoy R, Pocai A, et al. A comparative study of the binding properties, dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucose-lowering efficacy of the DPP-4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice Endocrinology, diabetes & metabolism (2018). PMID: 30815539 DOI: 10.1002/edm2.2 Source material

Publications

5 publications citing this product

  1. Ki-Young Kim, .et al. , Pharmaceutics, 2024, Jan 13;16(1):106 PMID: 38258116
  2. OHE El-Shoubashy, .et al. , JPC, 2020, 33, 59-70
  3. Sato T, .et al. , Sci Rep, 2019, Dec 2;9(1):18094 PMID: 31792328
  4. Chintan N. Koyani, .et al. , Front Physiol, 2018, 9: 1622 PMID: 30487758
  5. Koyani CN, .et al. , Biochem Pharmacol, 2016, Dec 1;145:64-80 PMID: 28859968

Added to your cart

View Cart Checkout
Loading...